Pfizer’s Covid Shot for Kids Faces Final Hurdle at CDC Meeting
(Bloomberg) -- A panel of experts who advise the U.S. Centers for Disease Control and Prevention on immunization are meeting Tuesday to discuss the Covid-19 vaccine for kids made by Pfizer Inc. and BioNTech SE.
The Food and Drug Administration said Friday that children age 5 to 11 can get the two-dose vaccine, which is given at 10 micrograms, a third of the dose adults receive. The Biden administration is planning a broad rollout of the shots focusing on schools, pediatricians' practices and pharmacies.
Read More: Covid Shots for Kids to Narrow Biggest Racial Vaccine Gaps
Some polls have indicated that a significant number of parents may opt not to vaccinate their children right away. The U.S. has so far purchased 115 million pediatric doses, more than enough to fully vaccinate the 28 million children in the 5-11 age group.
Data on use of the Pfizer-BioNTech vaccine in younger children is expected in coming months, and the shots the U.S. has on hand could also be used to immunize kids under 5 if they become eligible.
The virtual meeting of the Advisory Committee on Immunization Practices is scheduled to run from 11 a.m. to 5 p.m. and will be streamed online, according to an agenda posted on the panel's website.
Here's what to expect:
- During the morning, representatives from Pfizer will present data on their vaccine.
- After a 30-minute public comment period, the CDC will detail data concerning the safety of the vaccine, with information on adverse events including the heart ailment myocarditis.
- Later in the afternoon, the focus will be on clinical considerations and the group will discuss trial evidence, side effects and other issues.
- Near the end of the session, at about 4:15 p.m., the panel is expected to vote on recommendations. Voting language hasn't yet been made public.
After the vote, CDC Director Rochelle Walensky will decide whether to sign off on the recommendation. Then doctors, drugstores and other sites could begin giving shots.
In a White House briefing on Monday, President Joe Biden's coronavirus response coordinator Jeff Zients said that while shots for kids could be administered as early as this week, the program won't be fully up and running until the week of Nov. 8.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.